0.92

4.39% 0.0387

Esperion Therapeutics Inc (ESPR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ESPR Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.8813

Aprire:

$0.8898

Volume 24 ore:

4.84M

Relative Volume:

1.09

Capitalizzazione di mercato:

$174.30M

Reddito:

$116.33M

Utile/perdita netta:

$-209.25M

Rapporto P/E:

-0.434

EPS:

-2.12

Flusso di cassa netto:

$-135.49M

1 W Prestazione:

-3.16%

1M Prestazione:

-45.24%

6M Prestazione:

-56.19%

1 anno Prestazione:

-53.77%

Intervallo 1D:

$0.8519

$0.9389

Intervallo di 1 settimana:

$0.8191

$1.06

Portata 52W:

$0.8191

$3.94

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Nome

Esperion Therapeutics Inc

Settore

Healthcare (1155)

Industria

Drug Manufacturers - Specialty & Generic (1)

Telefono

734-887-3903

Indirizzo

3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI

Dipendente

240

Cinguettio

@esperioninc

Prossima data di guadagno

2025-03-04

Ultimi documenti SEC

ESPR's Discussions on Twitter

Confronta ESPR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ESPR Esperion Therapeutics Inc	0.92	174.30M	116.33M	-209.25M	-135.49M	-2.12
ZTS Zoetis Inc	153.47	65.50B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.03	46.99B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.18	45.96B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	14.87	17.04B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	291.38	12.77B	2.76B	1.11B	898.10M	22.77

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-18	Iniziato	Goldman	Neutral
2024-12-17	Iniziato	Cantor Fitzgerald	Overweight
2024-06-20	Downgrade	BofA Securities	Neutral → Underperform
2024-01-03	Downgrade	BofA Securities	Buy → Neutral
2023-11-20	Ripresa	JP Morgan	Neutral
2023-08-01	Aggiornamento	Northland Capital	Under Perform → Market Perform
2023-06-15	Aggiornamento	BofA Securities	Underperform → Buy
2023-03-16	Downgrade	BofA Securities	Neutral → Underperform
2023-03-16	Downgrade	Northland Capital	Market Perform → Under Perform
2023-03-07	Aggiornamento	Credit Suisse	Underperform → Neutral
2023-02-27	Ripresa	BofA Securities	Neutral
2023-02-24	Aggiornamento	Jefferies	Hold → Buy
2023-02-03	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2022-08-03	Downgrade	Credit Suisse	Neutral → Underperform
2022-05-05	Aggiornamento	JP Morgan	Underweight → Neutral
2022-03-10	Iniziato	H.C. Wainwright	Buy
2021-10-19	Downgrade	Credit Suisse	Outperform → Neutral
2021-10-14	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2021-05-05	Downgrade	Stifel	Buy → Hold
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-03-11	Iniziato	Morgan Stanley	Equal-Weight
2021-02-12	Downgrade	Jefferies	Buy → Hold
2021-02-09	Downgrade	Goldman	Neutral → Sell
2021-01-15	Downgrade	BofA Securities	Buy → Neutral
2020-11-10	Aggiornamento	Credit Suisse	Neutral → Outperform
2020-09-29	Ripresa	JP Morgan	Underweight
2020-08-11	Downgrade	Credit Suisse	Outperform → Neutral
2020-04-01	Ripresa	BofA/Merrill	Buy
2020-03-17	Aggiornamento	Citigroup	Neutral → Buy
2020-02-24	Downgrade	Northland Capital	Outperform → Market Perform
2020-02-14	Downgrade	Citigroup	Buy → Neutral
2019-09-16	Aggiornamento	Goldman	Sell → Neutral
2019-05-29	Downgrade	Goldman	Neutral → Sell
2019-05-06	Aggiornamento	BofA/Merrill	Underperform → Neutral
2019-04-26	Aggiornamento	Goldman	Sell → Neutral
2019-03-13	Aggiornamento	JP Morgan	Underweight → Neutral
2019-01-07	Reiterato	Needham	Strong Buy
2018-12-13	Iniziato	Goldman	Sell
2018-10-29	Aggiornamento	Northland Capital	Market Perform → Outperform
2018-10-16	Iniziato	BTIG Research	Buy
2018-08-17	Aggiornamento	Citigroup	Neutral → Buy
2018-07-11	Downgrade	Northland Capital	Outperform → Market Perform
2018-05-03	Downgrade	JP Morgan	Neutral → Underweight
2018-05-02	Downgrade	BofA/Merrill	Buy → Underperform

Mostra tutto

Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie

Apr 25, 2025

Esperion Reveals Next-Gen Cholesterol Treatment Strategy: FDA-Approved Non-Statin Leader Updates Growth Plans - Stock Titan

Apr 25, 2025

Esperion to Participate in The Citizens Life Sciences Conference - GlobeNewswire

Apr 25, 2025

Apr 24, 2025

Esperion unveils novel PSC treatment candidates By Investing.com - Investing.com Canada

Apr 24, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research

Apr 24, 2025

Esperion (ESPR) Advances ACLY Inhibitors for Rare Liver Disease Treatment | ESPR Stock News - GuruFocus

Apr 24, 2025

Esperion unveils novel PSC treatment candidates - Investing.com

Apr 24, 2025

Esperion Unveils Promising Research Supporting Lead - GlobeNewswire

Apr 24, 2025

New PSC Liver Disease Treatment Breakthrough: Promising Data Reveals Path to $1B Market Opportunity - Stock Titan

Apr 24, 2025

Apr 23, 2025

Esperion to Report First Quarter 2025 Financial Results on May 6 - The Manila Times

Apr 23, 2025

Esperion Q1 2025 Earnings Preview: What's Next for this FDA-Approved Cardiovascular Drug Maker? - Stock Titan

Apr 23, 2025

Apr 22, 2025

Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Apr 22, 2025

Apr 21, 2025